After Lengthy Delay, Polaris Ready To Take HCC Drug Into Phase III
This article was originally published in The Pink Sheet Daily
With an SPA, the Taiwan-financed, U.S.-based biotech hopes to obtain FDA approval in hepatocellular carcinoma with a single Phase III trial.
You may also be interested in...
After a Sept. 14 meeting with the FDA, the biotech is confident it can satisfy all points in a complete response letter - including the gout therapy's REMS.
HONG KONG - Phase III clinical trials are slated to start next year on anti-cancer drug ADI-PEG 20 by U.S.-based Polaris Group's Taiwan subsidiary TDW Pharmaceuticals following successful Phase II trials that included recovery by a cancer patient deemed to have six months to live several years ago
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.